International | US Home Company Products Resources News & Events Contact You are here: Home / Company / About iSTAR Medical About iSTAR Medical iSTAR Medical SA, founded in 2011 and headquartered in Wavre, Belgium, is a clinical-stage, medical technology company focused on the development of novel ophthalmic implants for patients with glaucoma. Glaucoma is the second leading cause of adult blindness globally. iSTAR Medical has exclusive rights to the STAR® biomaterial from the University of Washington in Seattle (USA) for ophthalmic use. The porous material exhibits outstanding anti-fibrotic and anti-inflammatory properties providing the foundation for the development of MINIjectTM, designed to be a best-in-class micro-invasive glaucoma surgery (MIGS) device. MIGS is the most promising and fastest-growing therapeutic option for the treatment of glaucoma. The fast-growing glaucoma surgical device market is expected to reach $1.84 bn worldwide by 2025.* iSTAR Medical’s management team and board have a successful track record in end-to-end product development, with proven clinical, regulatory and market access capabilities. The company is backed by specialised institutional and private investors. * Glaucoma Surgical Device Market Report, Market Scope 2020 About iSTAR Medical Vision & Values Management Team Board of Directors Scientific Advisors © Copyright - iSTAR Medical - Privacy Policy

International | US Home Company Products Resources News & Events Contact You are here: Home / News & Events / News / CEO Michel Vanbrabant to present at OIS Glaucoma virtual 2021 CEO Michel Vanbrabant to present at OIS Glaucoma virtual 2021 20th October 2021/in News iSTAR Medical was selected to present the latest data for MINIjectTM, its minimally-invasive glaucoma surgery (MIGS) device, at the OIS Glaucoma Innovation Showcase on 21st October 2021 at 1:20PM EDT. Michel Vanbrabant, CEO, will present newly available two year preliminary safety and efficacy results in ~50 patients from the STAR-I and STAR-II MINIjectTM trials. The results show a remarkable 39% reduction in intraocular pressure (IOP) at 2 years combined with a reduction in medication by about half. In addition, about half of patients remained medication-free. “The studies show that MINIject consistently demonstrates powerful and sustained performance in primary open angle glaucoma patients across regions. We are looking forward to offering this safe and intuitive procedure with low post-operative patient management to surgeons before the end of the year, upon CE-Marking approval,” revealed Vanbrabant. This virtual event will begin with a market overview followed by a showcase of several promising start-ups in the Glaucoma sector, and conclude with two deep-dive panel discussions. Throughout the event, you will be able to ask questions and network with other participants in real-time. Registration is free: here Share this entry News Press Releases Events © Copyright - iSTAR Medical - Privacy Policy